🧵 4. In a study of 529 obese patients, Wegovy improves symptoms of preserved ejection fraction (HFpEF) heart condition. Nearly 17-point improvement on symptom scale compared to placebo.
You are viewing a single comment's thread from:
🧵 4. In a study of 529 obese patients, Wegovy improves symptoms of preserved ejection fraction (HFpEF) heart condition. Nearly 17-point improvement on symptom scale compared to placebo.